GEN-MKT-18-7897-A
Jan 24, 2019 | Blogs, Forensic | 0 comments
Anyone with children will remember that moment in the hospital when the nurse pricks the heel of your tiny new baby to squeeze out a few drops of blood onto a card. It’s an anxious moment but it’s over in a flash, and necessary to screen for rare but serious health conditions. This dried blood spot sampling technique was first introduced 55 years ago, and it has become the method of choice for newborn screening around the world.
But what does this have to do with forensic testing of novel psychoactive substances, after all, it is quite a leap to talk about newborn babies and then onto designer drugs? While dried blood spot sampling and analysis had to overcome hurdles in the early days, particularly due to low analytical throughput, there is a very good reason for its increasing attention in recent years in other applications.
It offers a faster, simpler alternative to serum/plasma or whole blood analysis in drug monitoring for toxicological analysis. In the tech note LC-MS/MS Screening of 64 New Psychoactive Substances Using Dried Blood Spots (as an Alternative to Whole Blood) we demonstrate the advantages, and here’s a rundown:
Sounds good, so what’s the catch? The small sample volume also means that the concentration of the target analyte is potentially quite low (e.g., less than 1 ng/L), requiring a highly sensitive and selective analysis method for detection and quantification. But in theory, there isn’t a catch if there is a solution, mass spectrometry. It is now the most common technique reported in literature for dried blood spot analysis and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) sets the benchmark.
In our method, researchers use the highly sensitive QTRAP® LC-MS/MS in Multiple Reaction Monitoring (MRM) mode using the Scheduled MRM™ Algorithm. The method is applied to authentic samples, and results are compared to a validated whole blood method used for routine analysis of NPS, yielding similar results. LOD was between 1 and 10 ng/ml, no interference from matrix compounds was observed, and the method was proven to be specific and selective for the analytes.
Fill out the form on your right to download the 2018 Forensics Compendium to see this method in its full glory, along with recent advancements developed by the forensics team and a view on where LC-MS/MS technology could take forensics in the future.
In monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.
In drug discovery and development, Metabolite Identification (Met ID) plays a critical role in understanding biotransformation pathways, ensuring safety, and meeting regulatory requirements. Advanced mass spectrometry techniques have revolutionized this process, particularly through electron-based fragmentation methods such as Electron Activated Dissociation (EAD) and Electron Transfer Dissociation (ETD). While both techniques leverage electron interactions to generate informative fragment ions, they differ significantly in mechanism, performance, and suitability for Met ID workflows.
In analytical laboratories, performance is not optional. Whether supporting regulated pharmaceutical workflows, high-throughput CRO operations, clinical reporting, or food and environmental testing, your mass spectrometry and capillary electrophoresis systems are critical to productivity, compliance, and scientific confidence.
Posted by
You must be logged in to post a comment.
Share this post with your network